All In Biotech

Drug Trial Radar · NCT05417932

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

A Phase 1/ 2a, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Oct 26, 2022

Primary completion

Sep 2025

Study completion Oct 2025

Sponsor

Lead sponsor
SCG Cell Therapy Pte. Ltd.Industry
Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Conditions

  • Hepatitis B Virus Related Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Recurrent

Interventions

  • SCG101Biological

    Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SCG101Time frame: Start of SCG101 infusion until 100 days post SCG101 infusion
  2. Tumor response of SCG101 (Phase 2)Time frame: Start of SCG101 infusion until a complate response or partial response is observed, disease progression, and long term survival follow up up to 15 years

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • New York

    New York, New York · Recruiting

  • New York

    New York, New York · Recruiting

  • Hong Kong is.

    Hong Kong, Hong Kong · Not yet recruiting

  • Hong Kong NT

    Hong Kong, Hong Kong · Recruiting

  • Singapore

    Singapore, Singapore · Recruiting

  • Singapore

    Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.